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Abstract: The influenza A virus is one of the leading causes of respiratory tract infections 
in humans. Upon infection with an influenza A virus, both innate and adaptive immune 
responses are induced. Here we discuss various strategies used by influenza A viruses to 
evade innate immune responses and recognition by components of the humoral and cellular 
immune response, which consequently may result in reduced clearing of the virus and 
virus-infected cells. Finally, we discuss how the current knowledge about immune evasion 
can be used to improve influenza A vaccination strategies. 
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1. Introduction 
Influenza viruses belong to the family of orthomyxoviridae and are one of the leading causes of 
respiratory tract infections in humans [1]. Yearly, influenza viruses cause an estimated 3–5 million 
severe clinical infections and 250,000–500,000 fatal cases [2,3]. The genome of influenza A viruses 
consists of eight gene segments of single-stranded negative-sense RNA encoding 12 proteins: surface 
glycoproteins, hemaglutinin (HA) and neuraminidase (NA), two matrix proteins (M1 and M2), the 
nucleoprotein (NP), three polymerase complex proteins PB1, PB2 and PA, and four non-structural 
proteins NS1, NS2, PA-X and PB1-F2 [1,4].  
Influenza A viruses are subdivided, based on their surface glycoproteins; currently 17 subtypes of 
HA and nine subtypes of NA are known [5–7]. Seasonal influenza A viruses of the H1N1 and H3N2 
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subtype and influenza B viruses cause yearly epidemics [2]. This can be attributed to their ability to 
escape recognition by virus specific antibodies due to antigenic drift (Figure 1). As a result, seasonal 
influenza vaccines need to be updated almost annually to match the new epidemic strains and to 
remain efficacious [8].  
Figure 1. Antigenic drift and shift to escape immunity. The gradual accumulation of 
mutations, mainly in the highly variable globular head region of HA, causes the influenza 
virus to escape recognition by virus neutralizing antibodies and allows it to cause seasonal 
epidemic outbreaks. This phenomenon is called antigenic drift. The introduction of a novel 
subtype into the human population is called antigenic shift and may cause a pandemic 
outbreak in the naïve human population when the virus is efficiently transmitted from 
human to human, since antibodies directed against the novel subtype are absent. Past 
pandemic outbreaks were caused by exchange (re-assortment) of gene segments between 
two or more influenza strains, e.g., avian and human. However, recent studies in ferrets 
suggest that avian influenza viruses, like H5N1, could be directly transmitted from animal 
reservoirs into the human population, requiring only a small number of adaptive 
mutations [9] as indicated by the dotted line in this figure.  
 
 
Introduction in the human population of influenza A viruses with antigenically distinct HA 
molecules, including novel subtypes, is known as antigenic shift (Figure 1). When such an 
antigenically-distinct virus is transmitted efficiently from human to human, it may cause a pandemic 




influenza outbreak, since neutralizing antibodies to this virus are absent in the population at large [10]. 
Examples of pandemics include the Spanish flu of 1918 caused by a virus of the H1N1 subtype which 
killed 20–50 million people [11], the Asian flu of 1957 caused by a re-assorted H2N2 virus and the 
Hong Kong flu of 1968 caused by a re-assorted H3N2 virus. Each time, the pandemic virus replaced 
the subtype that circulated prior to the pandemic. In 1977, a virus of the H1N1 subtype was  
re-introduced, which did not result in a major pandemic, and this virus seasonally co-circulated with 
the H3N2 virus subtype until 2009. The first pandemic outbreak of the 21st century occurred in 2009 
when a novel H1N1 re-assorted virus of swine origin was introduced into the human population [12]. 
In addition, other influenza virus subtypes are transmitted from animals (in particular swine and avian 
influenza viruses) to humans occasionally [13,14]. For example, in 1999, there were three isolated 
cases of influenza A/H9N2 virus infections in humans displaying mild symptoms only [15]. During an 
outbreak of highly pathogenic avian influenza A virus of the H7N7 subtype in the Netherlands in 2003, 
89 human cases were reported of which one was fatal [16,17]. Larger is the impact of highly 
pathogenic avian influenza A/H5N1 viruses which have been transmitted on a regular basis from 
infected poultry to man since the first case was identified in 1997 in Hong Kong [18]. Since 2003, 
over 600 human cases have been reported, most of them suffering from severe pneumonia progressing 
to acute respiratory distress syndrome, 60% of the cases had a fatal outcome [19–23]. The reported 
case fatality rate most likely is an overestimate, since subclinical infections and mild cases are not 
reported [24]. So far, efficient human-to-human transmission has not been observed, although clusters 
of human cases have been reported [25–27]. Furthermore, recent studies have shown that, in principle, 
transmission of highly pathogenic H5N1 viruses amongst mammals is possible and that only a limited 
number of adaptive mutations are required for airborne transmission, emphasizing the pandemic 
potential of these viruses [9,28,29].  
Without lifelong protection against seasonal influenza virus infections and the threat of possible 
future pandemics, it is of great importance to have insight in how immunity against influenza A 
infections is formed and how influenza A viruses manage to evade these immune responses. In this 
review, we describe the role of innate and adaptive immunity against influenza A virus infections and 
evasion strategies used by influenza A viruses to escape immunity. Finally, we briefly discuss the 
impact on influenza A vaccine development. 
2. Innate Immunity 
The primary targets for influenza viruses are the epithelial cells that line the respiratory tract and 
which initiate an antiviral immune response upon detection of the virus. The first line of defense is 
formed by the innate immune system, which is quick but lacks specificity and memory. Innate 
immunity is formed by physical barriers (e.g., mucus and collectins) and innate cellular immune 
responses [30]. Here, we outline several of the innate defense mechanisms directed against influenza 
A infections.  
2.1. Sensing Of Influenza Virus Infection by Receptors of the Innate Immune System  
Influenza A virus infection results in the recognition of pathogen-associated molecular patterns 
(PAMPs) by pattern recognition receptors (PRRs) that initiate antiviral signaling cascades, resulting in 




the production of interferons (IFNs), cytokines and chemokines [31]. Three main categories of PRRs 
are involved in recognition of an influenza A infection and the induction of an IFN response: Toll like 
receptors (TLRs), retinoic acid inducible gene-I (RIG-I) receptors and nucleotide oligomerization 
domain(NOD)-like receptor family pyrin domain containing 3 (NLRP3) [32–34].  
The TLRs are the first receptors to recognize the influenza virus infection. TLR7 is an intracellular 
receptor that recognizes single stranded viral RNA (ssRNA) after the ribonucleoprotein complex has 
been degraded inside acidified endosomes [35,36]. TLR3 is another intracellular receptor that 
recognizes double stranded viral RNA (dsRNA) [37]. Other TLR receptors likely to sense an 
influenza virus infection are TLR2 and TLR4, which are present on the cell surface and recognize viral 
surface glycoproteins like influenza HA and NA [34,38–40]. At a later stage of infection, newly 
produced uncapped, 5'-triphosphates bearing viral RNAs are recognized by RIG-I receptors in the 
cytoplasm [41–44].  
NLRP3 is part of the NLRP3 inflammasome and is activated by dsRNA which subsequently 
activates caspase I, resulting in the proteolytic maturation of IL-1β and IL-18 [45].  
The signaling cascade of all activated TLRs, except for TLR3, starts with the activation of MyD88, 
which subsequently can activate tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6), 
either directly or via IL-1R-associated kinase-1 (IRAK 1), eventually leading to the activation of 
mitogen-activated kinases (MAPKs) and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB). TLR3 signaling cascade starts with the activation of TRIF (TIR-domain-containing 
adapter-inducing interferon-β) eventually activating NF-κB and interferon regulatory factor 3 (IRF3). 
TLR4 can also signal via the TRIF dependent pathway by formation of a TRAM-TRIF complex.  
Activation of RIG-I receptor by binding of viral 5'-triphosphates RNA or viral dsRNA to the 
repressor domain (RD) of RIG-I results in conformational changes exposing the caspase activation and 
recruitment domains (CARDs). These domains are ubiquitinated by IFN-inducible E3 ubiquitin ligase, 
tripartite motif 25 (TRIM25) [46]. RIG-I can then associate with mitochondrial antiviral signaling 
adaptor (MAVS; also known as IPS-1, VISA or Cardif), starting a signaling cascade that leads to the 
activation of IRF3 and NF-κB. The signaling cascades via TLRs and RIG-I receptors have been 
extensively reviewed by others [44,47–49] (Figure 2).  
All these pathways eventually result in the transcription of proinflammatory cytokines, chemokines 
and IFNs that activate the antiviral response and the recruitment of neutrophils, activation of 
macrophages and maturation of dendritic cells (DCs) [31]. So far, three IFN types have been 
identified [50]. Type I IFNs include IFN-α and IFN-β which have an important role in limiting viral 
replication [51,52]. Type I interferons secreted by infected cells act on IFN-α/β receptors (IFN-α/βR) 
of the same cell or neighboring cells, activating an antiviral signaling cascade that involves phosphorylation 
of tyrosine kinase 2 (Tyk2) and Janus kinase 1 (Jak1), also called, “just another kinase 1”, which then 
phosphorylate signal transducer and activators of transcription (STAT) 1 and STAT2. Phosphorylated 
STAT1 and 2 combine with IRF9 to form ISGF3 (IFN-stimulated gene factor-3 transcription factor 
complex) which is responsible for the transcription of >300 genes that encode for e.g., antiviral proteins 
(Table 1) that establish an antiviral state in the cell that limits viral replication [49] (Figure 3). IFN-β acts 
through a positive feedback loop on the IFN-β receptor which activates IFN stimulated gene factor 3 
(ISGF3), resulting in the expression of IRF-7. IRF-7 is phosphorylated in the presence of a viral 
infection and induces the expression of both IFN-α and IFN-β [53].  




Figure 2. The RIG-I signaling pathway and inhibition by influenza A viruses (Figure 
adapted from [48]). By-products of viral replication are 5'-triphosphates ssRNA and 
dsRNA which can bind to the RIG-1 receptor, leading to conformational changes, causing 
exposure of the CARDS which are ubiqutinated by TRIM25. Subsequently, RIG-1 
associates with MAVS and thereby starts a signaling cascade leading to activation of 
transcription factors IRF3, NF-κB and ATF-2/JunC, resulting in the transcription of IFN-β 
mRNA. Indicated in red are sites at which the influenza A virus interferes with this 
pathway, as explained in the text. 
 




Figure 3. The type I IFN signaling pathway and inhibition by influenza A viruses (Figure 
adapted from [48]). IFN-β produced by influenza virus-infected cells binds IFN receptors 
causing the phosphorylation of Tyk2 and Jak1. This is followed by binding and 
phosphorylation of STAT1 and STAT2 which subsequently form a complex with IRF9. 
This ISGF-3 complex acts as a transcription factor for >300 genes, several of which display 
an antiviral effect (see text). The expressed protein PKR is activated upon recognition of 
viral dsRNA, leading to inhibition of protein synthesis, including viral proteins. PKR is 
inhibited by the cellular protein P58IPK, however P58IPK activity is downregulated by 
binding cellular hsp40. The IRF7 protein is phosphorylated in the presence of influenza A 
virus, leading to activation of a positive feedback loop, causing the transcription of IFN-α 
and IFN-β. Indicated in red are mechanisms of the influenza A virus to interfere with this 
pathway, these interfering mechanisms are explained more extensively in the text.  
 




Table 1. IFN-induced antiviral proteins and their function. 
Protein Function  Reference 
MxA (Myxovirus 
resistance gene A) 
Inhibits viral replication by interfering with the viral 
ribonucleoprotein structure [54–56] 




Stops viral replication by means of activating RNAseL 
which results in degradation of viral and cellular RNA and 
eventually apoptosis of the virus infected cell 
[59,60] 
ISG15 (IFN-stimulated 
gene 15) Regulates a number of IFN-stimulated proteins [61] 
Viperin  Inhibits viral release by interfering with viral budding [62] 
Tetherin Inhibits formation of influenza virus particles [63,64] 
IFITMs Restrict viral entry [65] 
 
IFN-γ is the main type II IFN and contributes to the establishment of an effective adaptive cytotoxic 
T cell (CTL) response against the influenza virus infection. It regulates virus-specific CTL homeostasis 
in secondary lymph nodes and subsequent trafficking of CTLs to the site of infection [66]. Furthermore, 
IFN-γ plays an important role in memory CTL responses [67]. Type III IFNs, like IFN-λ, also control 
influenza A infections in the lung [68]. 
2.2. Macrophages  
During homeostasis, alveolar macrophages exhibit a relatively quiescent state, producing only low 
levels of cytokines, and suppress the induction of innate and adaptive immunity [69,70]. CCL2, 
produced by infected epithelial cells during the initial phase of the influenza virus infection, attracts 
alveolar macrophages and monocytes via their CCR2 receptor [71–73]. Activated macrophages 
enhance their pro-inflammatory cytokine response, including IL-6 and TNF-α [74,75]. Alveolar 
macrophages have a direct role in limiting viral spread by phagocytosis of apoptotic infected 
cells [40,76,77] and by phagocyte-mediated opsonophagocytosis of influenza virus particles [78]. They 
are also involved in regulating the adaptive immune response. Depletion of alveolar macrophages prior 
to influenza virus infection led to a reduction of antibody titers and reduced numbers of virus-specific 
CTLs post-infection [77]. In contrast to these beneficial effects, alveolar macrophages also pose a 
negative effect, since their activation also results in the production of nitric oxide synthase 2 (NOS2) 
and TNF-α which contribute to the severe pathology that can be the result of an influenza  
virus infection [71,79,80]. 
2.3. Natural Killer Cells 
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system. They are able to 
lyse infected cells in a MHC class I independent manner via a direct or indirect mechanism of 
recognition. The sialylated NKp44 and NKp46 receptors are bound by the HA proteins expressed on 
the surface of influenza virus-infected cells [81]. This results in direct lysis of the infected cell [82,83]. 
It was shown that mice lacking the NKp46 receptor equivalent, NCR-1, displayed increased morbidity 
and mortality following influenza A infection [84]. NK cells with their CD16 receptor (FcγRIII) can 




bind to the Fc portion of antibodies bound to influenza virus-infected cells and mediate lysis of these 
cells. This process is known as antibody-dependent cell cytotoxicity (ADCC) [85–87].  
2.4. Dendritic Cells 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) which form an important 
bridge between the innate and the adaptive immune system. During an infection, DCs initiate adaptive 
immune responses by the presentation of viral antigens to naïve and memory T and B lymphocytes 
(Figure 4) [69,88,89]. At steady state conditions, DCs constantly survey the lungs for invading 
pathogens or foreign material [90]. Once the lungs are infected with influenza A virus, the DCs can 
acquire the antigens via two distinct mechanisms. The first route is by direct infection of DCs by 
influenza A virus [91,92]. Proteasomes in the cytosol degrade viral proteins into small peptides which 
are transported to the endoplasmic reticulum (ER) via TAP (transporter of antigen processing), where 
they are loaded to MHC class I molecules. These MHC class I peptide complexes are then transported 
via the Golgi complex onto the cell membrane where they can be recognized by virus-specific CD8+ 
cytotoxic T cells (CTLs) (Figure 5) [88,93]. The second mechanism of antigen acquisition by DCs is 
through phagocytosis of virus particles or apoptotic epithelial cells [88,94–96]. Viral proteins are then 
degraded into smaller peptides in endosomes/lysosomes and presented on the cell surface in MHC 
class II peptide complexes which can be recognized by CD4+ T helper cells. T helper cells assist B 
cells to proliferate and mature into antibody-producing plasma cells. Via this route of antigen 
acquisition, DCs can also present epitopes to CD8+ T cells. This is also known as cross-presentation. 
For presentation of viral antigens to virus-specific T cells, activated DCs migrate to the draining lymph 
nodes [90,97–99].  
3. Adaptive Immunity 
The second line of defense against influenza A virus infection is the adaptive immune response. 
Overall, this highly specific response is relatively slow upon first encounter with a pathogen. However, 
as a result of the formation of immunological memory, the response is faster and stronger after a 
second encounter with the same pathogen. The adaptive immune response consists of humoral 
(virus-specific antibodies) and cellular (virus-specific CD4+ and CD8+ T cells) immunity. Here we 
summarize virus-specific recognition by components of the adaptive immune system and their 
contribution to clearance of influenza A virus infections. 
3.1. Humoral Immunity  
Influenza virus infection induces the production of influenza virus-specific antibodies by B cells 
[100–103]. In particular, antibodies directed to the viral HA and NA correlate with protective immunity.  
Antibodies directed to the trimeric globular head of HA can afford sterilizing immunity to influenza 
virus infection. By binding to the HA receptor binding site located in this region they can block virus 
attachment to host cells and/or block receptor-mediated endocytosis [104–106]. However, most 
antibodies directed against HA are influenza virus strain-specific and fail to neutralize intrasubtypic 
drift variants and viruses of other subtypes [6,10,107–109]. This is mainly due to the high variability in 




the HA globular head (see below). Of interest, humoral immunity elicited after an influenza virus 
infection does provide long-lasting antibody mediated protection against the strains that resemble the 
infected strain. This was exemplified during the pandemic of 2009 caused by an influenza virus of the 
H1N1 subtype. Elderly people that were exposed to influenza A/H1N1 virus in the 1950s had 
antibodies which cross-reacted with the pandemic strain and were relatively spared from contracting 
infections and developing disease [109–112]. Recently, broadly reacting antibodies directed against the 
conserved stem region of HA have been identified [113–120].  
Figure 4. Induction of humoral and cellular immunity. Induction of immune responses 
after a primary influenza A virus infection is indicated by solid arrows. The more rapid 
activation of virus-specific memory cell populations upon secondary encounter with an 
influenza A virus are indicated by dotted arrows. 
 
 
Antibodies to the other major glycoprotein, the viral NA, interfere with the last phase of the viral 
replication cycle and also exert protective immunity. NA is a sialydase and removes sialic acids from 
infected cells and budded virions, thereby facilitating efficient release and spread of newly formed 
viral particles [1]. Unlike HA-specific antibodies, NA-specific antibodies do not neutralize the virus. 
However, by inhibiting the enzymatic activity of NA, these antibodies limit the viral spread and thus 
shorten severity and duration of illness [121–125]. Furthermore, NA-specific antibodies may also 
contribute to clearance of virus-infected cells by facilitating ADCC [85]. 




In addition to HA and NA, influenza virus particles contain the minor glycoprotein M2. This 
tetrameric transmembrane protein has ion channel activity and plays an important role in unpacking 
the virus in the endosome [1]. A protective effect of M2-specific antibodies was first demonstrated in 
mice after passive transfer of M2-specific monoclonal antibodies [126,127]. M2-specific antibodies 
facilitate ADCC [87,128,129]. Since the M2 protein is highly conserved between various influenza A 
virus subtypes, M2-specific antibodies are likely to afford heterosubtypic immunity [130–137].  
After infection, antibodies are also induced against other viral proteins, including NP [138]. Since 
NP is highly conserved between influenza A viruses, these antibodies could potentially contribute to 
heterosubtypic immunity. Although NP-specific antibodies are non-neutralizing, it was shown in mice 
that they contribute to protective immunity [139,140]. However, their mode of action is poorly 
understood, but may include ADCC of infected cells and opsonisation of NP, resulting in improved 
T cell responses [141,142]. 
After primary infection with influenza virus, serum antibodies of the IgM, IgA and IgG isotypes are 
induced, whereas after secondary responses, IgM responses are not observed [143]. IgM antibodies can 
neutralize the virus, but also activate the complement system [144,145]. In humans, virus-specific 
serum IgA responses seem indicative for recent infection with influenza virus [146,147]. 
Virus-specific IgG antibodies correlate with long-lived protection, provided that the antibodies match 
the strains causing the infection [148–150]. In addition to serum antibodies, influenza virus infection 
also induces local mucosal sIgA antibody responses that protect airway epithelial cells from infection 
[149,151,152]. 
Young infants may be protected from influenza virus infection by maternal antibodies, when they 
match the incoming virus [153–157]. 
3.2. Cellular Immunity  
Influenza A virus infection induces a cellular immune response, including virus-specific CD4+ T 
cells and CD8+ T cells. These cells play an important role in regulation of the immune response and 
viral clearance respectively. 
3.2.1. CD4+ T Cells 
CD4+ T cells are activated after recognition of viral epitopes associated with MHC class II 
molecules and interaction with co-stimulatory molecules on APCs. Depending on the cytokine milieu, 
activation of naïve CD4+ T cells can result in the differentiation into CD4+ T helper 1 cells (Th1) or 
Th2, which can be distinguished based on their cytokine expression profiles [158]. Th2 cells produce 
IL-4, IL-5 and IL-13 and promote the activation and differentiation of B cells, resulting in antibody 
production [159–161]. The antibody response is strengthened by the induction of antibody class 
switching and somatic hypermutations affecting the variable region of the antibody, resulting in 
affinity maturation of the influenza-specific antibodies [162–165]. Th1 cells produce IFN-γ and IL-2 
and are mainly involved in promoting CTL responses [166,167], and are essential for the induction of 
memory CD8+ T cells [168–170]. Memory CD4+ T cells, induced after a primary influenza A virus 
infection, contribute to faster control of subsequent influenza A virus infections [171]. Lung-resident 
memory CD4+ T cells in particular have an important role in protection against secondary influenza A 




virus infections [172]. In addition to helper function, CD4+ T cells also display cytolytic activity 
[173,174]. It was shown that these cells play a role in protective immunity against influenza A virus 
infections in humans [175]. A more extensive review on the role of CD4+ T cells in heterosubtypic 
immunity can be found elsewhere [176].  
3.2.2. CD8+ T Cells 
Naïve CD8+ T cells are activated after recognition of viral epitopes associated with MHC class I 
molecules on APCs in the draining lymph nodes, and subsequently differentiate into CTLs. These 
CTLs migrate to the site of infection where they recognize and eliminate influenza virus infected cells 
and thereby prevent the production and spread of progeny virus [177]. Human influenza virus-specific 
CTLs are mainly directed against epitopes of the highly conserved internal viral proteins, like M1, NP, 
PA and PB2. Therefore, CTLs display a high degree of cross-reactivity with influenza A viruses of 
various subtypes [178–184]. T cell receptor (TCR) activation by a specific epitope-MHC class I 
complex results in a lytic response, mediated by the release of perforin and granzymes causing 
apoptosis of the infected cell [185–187]. Furthermore, proinflammatory cytokines are produced, like 
TNF-α, which also inhibit virus replication and enhance lytic activity [185,188–191]. Also, FasL 
expression is upregulated which promotes apoptosis of infected cells [187]. After infection, a pool of 
long-lived antigen-specific central memory and effector memory CD8+ T cells is formed, which form 
the basis for more rapid and stronger recall responses upon secondary infections [192–201].  
Much of the current knowledge about the protective role of CD8+ T cells in influenza A virus 
infections has been obtained from mouse studies which showed that CD8+ T cells contribute to  
homo- and heterosubtypic immunity [202–209]. Evidence that CTLs protect against influenza in 
humans is sparse. A recent study indicated the presence of heterosubtypic memory CD4+ and CD8+ T 
cells against the 2009 pandemic H1N1 virus in naïve individuals [210]. It was shown that the extent of 
lytic activity of PBMC inversely correlated with the extent of virus shedding after experimental 
infection of subjects that lacked antibodies to the life-attenuated strain used for infection [211]. More 
circumstantial evidence for a protective role of CD8+ T cells in heterosubtypic influenza infections in 
humans stems from epidemiological studies. People who had a symptomatic influenza A infection with 
the H1N1 strain prior to the 1957 pandemic were partially protected from infection with the pandemic 
H2N2 strain [212,213]. A similar trend was found in isolated infections with the H5N1 [214].  
3.2.3. Regulatory T Cells and Th17 Cells 
In addition to the activation of virus-specific CD4+ T cells and CD8+ T cells, two other cell types 
are activated, namely forkhead box P3 (FOXP3)+ regulatory T cells (Tregs) and T helper 17 cells 
(Th17). Tregs play an important role in balancing the immune response during infection. They control 
CD4+ T helper cell and CTL responses in order to prevent immunopathology of infected tissues 
[191,215,216]. Th17 cells produce IL-6 which inhibits the effects of Tregs and therefore promote T 
helper responses [215]. Furthermore, Th17 have a role during influenza infections in counteracting 
secondary bacterial infections, e.g., S. aureus pneumonia. Influenza A virus infections may promote 
secondary bacterial pneumonia by suppressing Th17 cells in an type I IFN-dependent manner [217]. 




4. Evasion of the Antiviral Immune Response by Influenza Viruses 
Immune pressure on influenza A viruses forces them to adopt strategies to evade immunity. Binding 
of influenza viral proteins to various components of the innate immune system leads to their inhibition 
(Figures 2 and 3) [48], whereas a combination of immune pressure in the human population and the 
high mutation rate of the influenza A virus leads to the generation of new virus strains that escape the 
existing adaptive humoral and cellular immune responses (Figures 1 and 5).  
4.1. Escape from Innate Immunity  
Influenza A viruses have adopted various strategies to evade the antiviral nature of the innate 
immune system. 
In particular, the NS1 protein contributes to antagonizing the antiviral innate immune response. 
Cells infected with genetically modified influenza viruses with a non-functional NS1 gene displayed 
stronger IFN responses than cells infected with wild type virus. Viruses with a NS1 defect also display 
reduced virulence after infection of mice and pigs [218–224]. NS1 inhibits RIG-I receptor signaling by 
various means. The NS1 protein blocks the recognition of 5'-phosphorylated viral ssRNA by the RIG-I 
receptor [42]. More downstream of the RIG-I signaling pathway, NS1 prevents oligomerization of 
TRIM25 by interacting with the coiled coil domain, and so inhibits TRIM25-mediated RIG-I CARD 
ubiquitination which is essential for downstream signaling [225]. Finally, activation and nuclear 
translocation of IRF-3, NF-κB and ATF-2/c-Jun is also prevented by NS1 [226–229]. Hereby NS1 
limits RIG-I mediated transcriptional activation of the IFN-β promoter [230,231]. NS1 also alters host 
cell gene expression by binding to CPSF30 (cleavage and polyadenylation specificity factor); it 
prevents polyadenylation of the 3' end of host pre-mRNA [232–234]. Furthermore, NS1 limits gene 
expression in general, interfering with the mRNA export machinery [235,236]. 
NS1 is not the only viral protein that restrains the innate immune system. Both influenza PB2 
(especially variants containing an aspartic acid at position 9) and PB1-F2 (only variants containing a 
serine at position 66) limit the production of IFN-β through association with MAVS [237–241].  
Viral proteins PB2, PB1 and PA form the influenza polymerase complex, the main function of 
which is viral RNA and mRNA synthesis. In addition, it is also involved in cap-snatching of host 
mRNAs and thereby reduces host cell gene expression including that of IFN-β [242–246].  
The recently discovered PA-X viral protein is able to repress cellular gene expression, especially 
those genes involved in regulating the initiation of the cellular immune response [4]. 
As described above, influenza A virus infection leads to the production of antiviral PKR (Table 1). 
In order for PKR to limit viral replication, it first needs to be activated by viral dsRNA. PKR activation 
is under tight regulation of the cellular p58IPK protein which inhibits PKR activity, but is inactive when 
it forms a complex with heatshock protein 40 (hsp40) [247,248]. Binding of NP to the p58IPK-hsp40 
complex releases p58IPK, and thereby NP inhibits the effects of PKR [249]. In contrast, the influenza 
M2 protein, which also binds the p58IPK-hsp40 complex, inhibits p58IPK release and thereby limits 
protein synthesis which eventually leads to host cell apoptosis, possibly enhancing viral particle 
release [250].  




By encapsidating influenza A viral RNA, the NP protein is likely to reduce the formation of 
dsRNA, which could otherwise lead to activation of RIG-I signaling. Since most PRRs are located 
inside the cytoplasm, the nuclear replication strategy of the influenza A virus also prevents the 
recognition of viral RNA by cytosolic PRR.  
In addition to limiting the production of type I IFNs, influenza A virus also disturbs type I IFN 
receptor signaling. Influenza A virus infection induces the expression of SOCS (suppressor of 
cytokine signaling) proteins which inhibit IFN α/β receptor signaling on the level of JAK/STAT  
activation [251,252].  
Besides interfering with innate signaling, influenza A viruses are also able to counteract cells of the 
innate immune system. For example, influenza virus infection of monocytes impairs their ability to 
differentiate into mature DCs [253]. Furthermore, it was shown that NS1 can inhibit DC maturation, 
and so indirectly limit the induction of virus-specific CD8+ T cell responses [254]. The NK response 
elicited during an infection is also evaded by the influenza A virus [255]. The gradual mutation of 
glycosylation sites of influenza virus HA proteins leads to reduced NK recognition of the HA on  
virus-infected cells [256]. Downregulation of the ζ chain of NKp46 receptors by free HA proteins 
results in impaired signaling and thereby decreased cytotoxicity of NK cells [257]. Furthermore, 
influenza A virus can directly infect and kill NK cells [258].  
4.2. Escaping the Humoral Immune Response  
Various mechanisms contribute to immune evasion of influenza A viruses from the humoral 
immune response. Due to the lack of proofreading activity, the transcription of viral RNA by the viral 
RNA polymerase is error prone and results in mis-incorporation of nucleotides. As a result, quasi 
species of viruses are formed with random mutations in the genome. Under the selective pressure of 
antibodies that are present in the human population, induced after influenza virus infections and/or 
vaccination, variants are positively selected from the quasi species that have accumulated amino acid 
substitutions in the antigenic sites of HA that are recognized by virus-neutralizing antibodies. This 
phenomenon is known as antigenic drift and allows the virus to evade recognition by antibodies and to 
cause recurrent influenza epidemics yearly (Figure 1) [8,10,259].  
Introduction of influenza A viruses of a novel antigenically distinct subtype into the human 
population is known as antigenic shift and may cause a pandemic outbreak, since neutralizing 
antibodies against the new virus strain are absent in the population at large (Figure 1) [10]. 
Introduction of antigenically distinct viruses can occur after zoonotic transmission. However, in most 
cases, pandemics were caused by viruses that had exchanged gene segments between human and avian 
or swine influenza A viruses [260,261]. For re-assortment to take place, cells need to be infected with 
two influenza A viruses simultaneously [262]. Since epithelial cells of the swine respiratory tract have 
receptors for both avian and human influenza A viruses, this species can serve as a mixing vessel for 
the emergence of re-assorted influenza A viruses [263–267]. The 1957 A/H2N2 pandemic was caused 
after re-assortment of human and avian influenza viruses, as was the 1968 A/H3N2 pandemic virus. 
The virus that caused the 2009 A/H1N1 pandemic emerged after multiple re-assortment events 
between avian, swine and human influenza A viruses [12,261,268–271]. The emergence of the 2009 
pandemic strain highlights the importance of pigs as mixing vessels for influenza A viruses. A recent 




study suggests that besides the pig, the quail could also serve as a mixing vessel for emerging  
re-assorted influenza A viruses [272]. 
Of interest, functionally important and conserved sequences in the surface proteins, like the fusion 
peptide, are inaccessible for antibody recognition, since they are buried inside the protein [273]. 
Similar strategies to evade antibody recognition are shared by other viruses, like human 
immunodeficiency virus (HIV) [274,275]. 
4.3. Escaping the Cellular Immune Response  
Viruses have adopted various strategies to evade recognition by virus-specific T cells. For example, 
viruses with a large DNA genome (e.g., herpes viruses) can encode proteins that interfere with various 
steps in the antigen processing and presentation pathways [276]. Most RNA viruses, including 
influenza viruses, have relatively small genomes and limited coding capacity. However, they can 
evade recognition by T cells through their high mutation rates and the selective pressure exerted by 
virus-specific T cells.  
Relatively more non-synonymous mutations are observed in the CTL epitope regions of influenza 
virus NP than in the rest of the protein, indicating that CTL epitopes are under selective pressure [277]. 
However, mutations flanking CTL epitopes may also affect the liberation of antigenic peptides from 
the protein by the proteasome or transport by TAP into the ER (Figure 5) [278–280], as was 
demonstrated for HIV [281]. 
Amino acid substitutions inside CTL epitopes may affect presentation of the epitope in different 
ways. Amino acid substitutions at an anchor residue may result in complete loss of the epitope, since it 
may no longer bind to its corresponding MHC class I molecule (Figure 5) [282–286]. Mutations at 
TCR contact residues can affect recognition by specific T cells, since the epitope no longer matches 
the specificity of the TCR (Figure 5) [283,284,287,288]. These types of mutations have been observed 
in escape mutants of viruses that chronically infect their host, like HIV-1 [289,290]. Both types of 
amino acid substitutions also have been observed during the evolution of seasonal A/H3N2 influenza 
viruses [283,285,286]. An example of a mutation at an anchor residue is the R384G substitution in the 
HLA-B*2705 restricted NP383–391 epitope [285]. This substitution considerably affected the human 
virus-specific CTL response in vitro [282]. It is remarkable that this mutation reached fixation rapidly, 
despite the fact that it is recognized by a minority of human subjects only. This could be explained by 
strong intra-host advantages and founder effects in a theoretical model [291]. 
An example of amino acid variation at TCR residues includes that observed in the HLA-B*3501 
restricted NP418–426 epitope [287,288]. Variation in this epitope displays signs of antigenic drift [292], 
and dictates the specificity of the CTL response to this epitope and also forms an explanation for 
cross-reactivity of CTL against contemporary viruses with historic strains [293]. Of interest, functional 
constraints may limit variation in CTL. For example, the M158–66 epitope from the matrix protein is 
highly conserved, despite its immunodominant nature and its restriction by HLA-A*0201, which has a 
high prevalence in the human population. Influenza viruses do not tolerate mutations in this epitope 
without loss of viral fitness [277,294]. 




Figure 5. MHC class I presentation of influenza A virus epitopes and viral escape. This 
figure represents a virus-infected cell and the presentation of viral epitopes by MHC class I 
molecules. The virus can escape recognition by virus specific CTLs by: (1) Mutations in 
TCR contact residues of CTL epitopes in order to prevent recognition of the epitope MHC 
class I complex by specific CTLs, or (2) mutating the anchor residues of the CTL epitope 
which prevents binding of the epitope to MHC class I molecules. Furthermore, mutations 
outside the CTL epitope may affect antigen processing by the proteasome or transport via 
the TAP respectively (3 and 4). 
 
 
The R384G mutation in the NP383–391 epitope was also detrimental to viral fitness and was only 
tolerated in the presence of functionally compensatory co-mutations [295,296]. At present, it is 
unknown if influenza viruses can also accumulate mutations flanking CTL epitopes in order to prevent 
efficient processing and presentation of these epitopes. Of interest, amino acid variation in the HA of 
influenza A/H3N2 viruses was also associated with escape from recognition by CD4+ T cells, but not 
with escape from recognition by antibodies [297].  




5. Implications for Vaccine Development 
5.1. Current Influenza Vaccines  
Currently used seasonal influenza vaccines are predominantly inactivated vaccine preparations. 
Their use aims at the induction of strain-specific antibodies that match the epidemic strains [298,299]. 
Although these vaccines are considered safe and efficacious, they also have some drawbacks that are 
addressed by new vaccine technologies [300]. As described above, antigenic drift of influenza viruses 
allows the seasonal viruses to escape the neutralizing activity of antibodies induced by previous 
infections or vaccination. Therefore, the vaccine fails to afford life-long protection and needs to be 
updated almost annually [301]. Furthermore, the production of the vaccine takes several months, so 
the recommendation for the vaccine strains of the upcoming influenza season is made months in 
advance [301]. In most influenza seasons, the predicted vaccine strains match the epidemic strains. 
Occasionally however, a predicted influenza vaccine strain does not match the circulating strain, 
resulting in suboptimal protection afforded by the vaccine [302–304]. In the event of an emerging 
pandemic outbreak, the time needed to produce and distribute a pandemic influenza vaccine is also a 
major drawback [305–307]. Seasonal influenza vaccines do not afford protection against pandemic 
strains of novel subtypes, since the vaccine-induced antibodies do not cross-react and cross-reactive 
CD8+ T cell responses are induced inefficiently.  
Alternatively, cold-adapted live-attenuated seasonal influenza vaccines are used [308–311]. The 
advantage of live-attenuated vaccines is that they also elicit cellular immune responses [312,313] and 
mucosal immunity [310]. More recently, live-attenuated influenza vaccines have been developed by 
disrupting NS1 activity through deletion or truncation of the NS1 gene [221,223,224,228,314]. Hence, 
the virus is unable to interfere with the innate immune response.  
5.2. Novel Vaccines  
Ideally, seasonal vaccines are used that induce broad-protective immunity against drift variants and 
potentially pandemic viruses of novel subtypes. Currently-used inactivated vaccines may even 
interfere with the induction of cell-mediated immunity otherwise induced by natural infections, 
especially in young children that are still immunologically naïve to influenza viruses. In this way, 
inactivated vaccines can hamper the development of heterosubtypic immunity [315–319]. Thus, the 
development of vaccines that induce broadly neutralizing antibodies and preferably long-lasting 
heterosubtypic CTL responses is desirable.  
Since viral proteins like NP and M1 are highly conserved, they are likely targets for the induction of 
cross-reactive T cell responses [320]. Induction of efficient CTL responses depends on effective 
endogenous antigen processing and presentation by MHC class I. This requires effective delivery of 
viral proteins into the cytosol. Several cytosolic delivery vaccine candidates are now under 
investigation, including DNA vaccines, recombinant viral vectors, ISCOMS and virosomes, some of 
which already have made it into clinical trials [321–327]. Also, the induction of cross-reactive 
antibodies has attracted attention in recent years; antibodies directed against the more conserved stem 
region of the HA molecule are of especial interest. In contrast to the subtype-specific antibodies 
induced against the globular head of HA, these HA stem-specific antibodies display broad-neutralizing 




activity against multiple influenza virus subtypes [113,114]. Using this stem region as an immunogen, 
broadly protective antibody responses could be induced [117,328].  
Also, the ectodomain of the M2 protein is highly conserved and antibodies induced against this 
region afford protection against challenge infection [133,136,137,329,330]. The mode of action is not 
neutralization per se, since M2 is a minor antigen on virus particles. However, since it is also 
expressed on the surface of infected cells, ADCC is probably responsible for the protective effect of 
these antibodies [135].  
Thus, vaccines that induce both humoral and cell-mediated immune responses directed to 
conserved regions of influenza A virus, in addition to strain-specific antibodies, are likely to afford 
protective immunity to a large variety of influenza A viruses, including drift variants and viruses of 
novel subtypes. 
6. Concluding Remarks  
Our knowledge of the complexity of interaction between host immune responses and variable 
pathogens, like influenza viruses, has increased tremendously. Insight has been obtained on how 
influenza A viruses evade recognition by components of the immune system. Although these insights 
have helped us to decrease both morbidity and mortality, mainly by developing effective seasonal 
vaccines, there are still gaps in our understanding that provide room for improvement for the 
development of more broadly protective vaccines. The induction of CTL responses to conserved 
epitopes, preferably those that are under functional constraints, may be a venue to develop broadly 
protective vaccines. Current research also focuses on cross-neutralizing antibody responses directed to 
more conserved regions of the surface proteins. If these regions are also under functional constraints, 
vaccines aimed at the induction of antibodies against these regions would suffer to a lesser extent in 
terms of variability in the target region. 
Collectively, the new developments may counteract the variable nature of influenza viruses 
and yield vaccines that afford protection against both seasonal influenza viruses and future 
pandemic strains.  
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